# Trade Mark Journal No.2026/017 24 April 2026

## WO0000001898233 (40,42)

Office of origin: Benelux Office for Intellectual Property (BOIP)

Date of International Registration:21 October 2025
Date of designation in the UK: 21 October 2025

Class 40
  Custom manufacture of therapeutic iPSC-based cells, iPSC-based cells for use in cell therapies and iPSC-based allogeneic edited cells for use in therapies, for others; custom manufacture of iPSC-based allogeneic cells for use in cell therapies.
Class 42
  Scientific research, design and technological development services in the fields of scientific iPSC-based cell cultures, iPSC-based cell therapies, and iPSC-based gene-edited cell therapy; scientific research, design and development of manufacturing processes in the fields of cell culture, cell therapy, and gene edited cell therapy, for others; scientific consultation services in the field of biotechnology, specifically in relation to iPSC-based cell culture, iPSC-based cell therapy, or iPSC-based gene edited cell therapy manufacturing.

Celyntra Therapeutics SA

Representative: NLO Shieldmark B.V., New Babylon City Offices Anna van Buerenplein 21 A, NL-2595 DA Den Haag, NETHERLANDS